TY - JOUR
T1 - New Horizons in the Treatment of Corneal Endothelial Dysfunction
AU - Rocha-De-Lossada, Carlos
AU - Rachwani-Anil, Rahul
AU - Borroni, Davide
AU - Sánchez-González, José María
AU - Esteves-Marques, Raquel
AU - Soler-Ferrández, Fernando Luis
AU - Gegúndez-Fernández, Jose Antonio
AU - Romano, Vito
AU - Livny, Eitan
AU - Rodríguez Calvo-De-Mora, Marina
N1 - Publisher Copyright:
© 2021 Carlos Rocha-de-Lossada et al.
PY - 2021
Y1 - 2021
N2 - The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.
AB - The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.
UR - http://www.scopus.com/inward/record.url?scp=85111095647&partnerID=8YFLogxK
U2 - 10.1155/2021/6644114
DO - 10.1155/2021/6644114
M3 - Review article
AN - SCOPUS:85111095647
SN - 2090-004X
VL - 2021
JO - Journal of Ophthalmology
JF - Journal of Ophthalmology
M1 - 6644114
ER -